Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic recombinant alpha-2 interferon therapy in relapsing multiple sclerosis.

D L Camenga, K P Johnson, M Alter

    Archives of Neurology
    |December 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Hidradenitis suppurativa].

    Dermatologie (Heidelberg, Germany)·2024
    Same author

    Dendritic and parallel processing of visual threats in the retina control defensive responses.

    Science advances·2020
    Same author

    [Cutaneous squamous cell carcinoma].

    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2020
    Same author

    Increasing rates of surgical treatment for paediatric tibial shaft fractures: a national database study from between 2000 and 2012.

    Journal of children's orthopaedics·2019
    Same author

    Inpatient surgical treatment of paediatric proximal humerus fractures between 2000 and 2012.

    Journal of children's orthopaedics·2018
    Same author

    Development and Characterization of 12 Novel Polymorphic Microsatellite Loci for the Mammal Chewing Louse Geomydoecus aurei (Insecta: Phthiraptera) and a Comparison of Next-Generation Sequencing Approaches for Use in Parasitology.

    The Journal of parasitology·2017
    Same journal

    Incorrect Table Entries and Word.

    Archives of neurology·2016
    Same journal

    IDEAL for CCSVI Research-Reply.

    Archives of neurology·2013
    Same journal

    Atlas of Inherited Metabolic Diseases, 3rd ed.

    Archives of neurology·2013
    Same journal

    Error in byline: in heterogeneity of coenzyme q10 deficiency: patient study and literature review.

    Archives of neurology·2013
    Same journal

    This month in archives of neurology.

    Archives of neurology·2013
    Same journal

    About this journal.

    Archives of neurology·2013
    See all related articles

    Recombinant-DNA-produced alpha-2 interferon did not show clear therapeutic benefits for multiple sclerosis (MS) patients. While well-tolerated, it did not prevent neurological worsening or disease progression post-treatment.

    Area of Science:

    • Neuroimmunology
    • Biotechnology
    • Clinical Trials

    Background:

    • Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
    • Recombinant-DNA technology offers novel therapeutic avenues for autoimmune conditions.
    • Previous treatments for MS have shown variable efficacy.

    Purpose of the Study:

    • To evaluate the efficacy and safety of recombinant-human interferon-alpha-2 in patients with multiple sclerosis.
    • To determine if alpha-2 interferon can reduce exacerbation rates and slow disease progression in MS.
    • To assess the long-term effects of alpha-2 interferon treatment in MS patients.

    Main Methods:

    • A placebo-controlled, double-blind, randomized trial involving 98 patients with clinically definite MS.

    Related Experiment Videos

  • Patients self-administered 2 x 10(6) IU of alpha-2 interferon or placebo three times weekly for up to 52 weeks.
  • Neurological status and exacerbation rates were monitored throughout the trial and during a three-month follow-up period.

    • Main Results:

    • Alpha-2 interferon was well-tolerated with minimal side effects.
    • Both interferon and placebo groups showed a sharp reduction in exacerbation rates during treatment.
    • During follow-up, more interferon patients experienced neurological worsening and a shift to progressive MS compared to placebo.

    Conclusions:

    • Recombinant-human interferon-alpha-2 did not demonstrate a clear therapeutic benefit for multiple sclerosis.
    • The observed increase in neurological worsening and disease progression in the interferon group warrants further investigation.
    • Alpha-2 interferon is not recommended as a treatment for multiple sclerosis based on this trial.